Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Initiation of the Iomab-B's pivotal Phase 3 trial in AML refractory/relapsing patients

Source Link:: http://www.actiniumpharma.com/products/pipeline/iomab-b/

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CPXX

100%

MBRX

100%

ATNM

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment Iomab-B works by ablating the patient’s bone marrow and leukemia thus paving the way for a transplant. We licensed Iomab-B from the Fred Hutchinson Cancer Research Center, which is widely considered the “temple” of transplant and it has been studied in over 250 patients to date. Our upcoming pivotal trial will enroll 150 patients and is expected to read out top line results in the second half of 2018.

http://www.actiniump...

Additional Relevant Details The company's most advance therapy is Iomab-B, which is the subject of a pivotal Phase 3 trial initiated in June to evaluate its efficacy as an induction and conditioning agent used to prepare patients 55 and older with relapsed or refractory AML for a hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT).

http://www.actiniump...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 10, 2016

Occurred Source:

http://www.actiniumpharma.com/news-media/press-releases/detail/177/with-impressive-data-in-tow-actinium-pharma-an-overlooked

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Iomab-b